Delix Therapeutics Advances Oral Neuroplastogen With $100M Series C
BEDFORD – Delix Therapeutics has secured a wave of venture capital to advance an experimental depression pill engineered to rebuild brain connections without causing hallucinations. The financing brings together major pharmaceutical and institutional backers as biotechnology firms race to simplify psychedelic medicine for routine outpatient use.
The oversubscribed Series C round totaled $100 million and was led jointly by Johnson & Johnson through its venture arm, JJDC, and the Dementia Discovery Fund at SV Health Investors. Existing investors including RA Capital, Artis Ventures, OMX Ventures, and UC Investments also participated alongside the IFM Fund at UC Davis Health, where the underlying university research originated. As part of the deal, Christian Jung of SV Health Investors and a representative from JJDC joined the company board.
The new capital will fund a controlled Phase II clinical trial for DLX-001 (Zalsupindole), an oral compound derived from the chemical structure of mebufotenin. Unlike traditional psychedelics like psilocybin, Zalsupindole is designed as a neuroplastogen that promotes synaptic growth in the prefrontal cortex while avoiding hallucinatory or dissociative effects. An earlier study of 18 adults with recurring Major Depressive Disorder (MDD) showed an average symptom reduction of roughly 50% after eight days, with benefits lasting four weeks past the final dose.
Still, clinicians caution that those early results came from a small trial without a placebo group, leaving larger blinded studies scheduled for early 2027 to test true efficacy. The fundraising also follows a difficult stretch in 2025 when Delix reduced staff and parted ways with its chief medical officer.
Beyond depression, Delix plans to direct proceeds toward preclinical programs targeting Alzheimer’s disease, Parkinson’s disease, and substance use disorders.
The investment highlights a familiar structural divide in regulated drug development. Botanical products and clinic bound psychedelics often struggle with insurance reimbursement, specialized facility bottlenecks, and inconsistent patient access. By isolating therapeutic mechanisms into standardized oral pills that fit existing pharmacy and prescription channels, pharmaceutical backers are betting that commercial durability favors familiar delivery formats over complex clinical experiences.






































